BACKGROUND Prostate cancer is the most common cancer among men in the UK. Prostate-
specific antigen testing followed by biopsy leads to overdetection, overtreatment as well as …

Background Prostate cancer is a major public health problem with considerable
uncertainties about the effectiveness of population screening and treatment options. We …

Introduction Overtreatment of localised prostate cancer is substantial despite increased use
of active surveillance. No randomised trials help define how to monitor patients or when to …

PURPOSE: There is continuing controversy over the most appropriate treatment for screen
detected and clinically localized prostate cancer, and increasing interest in monitoring such …

Background The comparative effectiveness of treatments for prostate cancer that is detected
by prostate-specific antigen (PSA) testing remains uncertain. Methods We compared active …

Objectives To present the baseline patient‐reported outcome measures (PROM s) in the
Prostate Testing for Cancer and Treatment (ProtecT) randomized trial comparing active …

Background Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and
69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer …

Introduction Focal therapy for prostate cancer is a radical paradigm shift in the management
of men with localised prostate cancer. It involves locating and destroying only the areas of …

Study Type–Therapy (case series) Level of Evidence 4 What's known on the subject? and
What does the study add? Active surveillance is an established management strategy for …

Background Radical prostatectomy and radiation therapy for prostate cancer have side
effects and unclear survival benefits for early stage and low-risk disease. Prostate cancer …